{"groups":[{"description":"Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nNivolumab: Given IV","id":"FG000","title":"Arm 1 A Lead-In (Azacitidine, Nivolumab)"},{"description":"Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nNivolumab: Given IV","id":"FG001","title":"Arm 1 B (Azacitidine, Nivolumab)"},{"description":"Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nIpilimumab\n\nNivolumab: Given IV","id":"FG002","title":"Arm 2 A Lead-In (Azacitidine, Nivolumab, Ipilimumab)"},{"description":"Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nIpilimumab\n\nNivolumab: Given IV","id":"FG003","title":"Arm 2 B (Azacitidine, Nivolumab, Ipilimumab)"},{"description":"Patients will receive therapy with nivolumab IV infusion on Day 8 and Day 22 (+/-3 days) of each 5-azacyidine cycle for first 4 cycles or until CR (whichever occurs earlier) followed by a maintenance regimen (one dose of nivolumab on Day 8 of each cycle of 5-azacytdine). Venetoclax will be administered orally daily on Days 1-21 of the first cycle; and Days 1-14 or Days 1-21 for subsequent cycles.\n\nAzacitidine: Given SC or IV\n\nVenetoclax: Given Orally\n\nNivolumab: Given IV","id":"FG004","title":"Arm 3 A Lead-In (Azacitidine, Nivolumab, Venetoclax)"},{"description":"Patients will receive therapy with nivolumab IV infusion on Day 8 and Day 22 (+/-3 days) of each 5-azacyidine cycle for first 4 cycles or until CR (whichever occurs earlier) followed by a maintenance regimen (one dose of nivolumab on Day 8 of each cycle of 5-azacytdine). Venetoclax will be administered orally daily on Days 1-21 of the first cycle; and Days 1-14 or Days 1-21 for subsequent cycles.\n\nAzacitidine: Given SC or IV\n\nVenetoclax: Given Orally\n\nNivolumab: Given IV","id":"FG005","title":"Arm 3 B (Azacitidine, Nivolumab, Venetoclax)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"85"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"47"},{"groupId":"FG004","numSubjects":"6"},{"comment":"There were Zero participants enrolled on Arm 3 B due to no responses in the lead in phase.","groupId":"FG005","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"85"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"47"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}